Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02378883 : Apollo™ Onyx™ Delivery Micro Catheter Post Market Safety Study
PhasePhase 4
AgesMin: N/A Max: N/A
Eligibility
Inclusion Criteria:

- The Subject or Subject's legally authorized representative has signed and dated an
informed consent form.

- The Subject has a confirmed diagnosis of a brain AVM.

- The Subject is clinically and neurologically stable for a minimum of 48 hours prior
to embolization.

- The Subject has a life expectancy of at least 1 year.

- The Subject agrees to and is capable of completing all study-required procedures.

Exclusion Criteria:

- Current participation in another investigational drug or device study that evaluates
treatments for brain AVMs or other cerebrovascular disease.

- The Subject has a bleeding disorder.

- The Subject is not a candidate for the use of vasodilators.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02378883      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740